This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
EMD Millipore
other brands :
Oncogene Research Products, Calbiochem, Novagen, Merck, Upstate Biotechnology, Chemicon, LINCO, Novabiochem, Guava
product type :
antibody
product name :
PIR121-1/Sra-1 Antibody
catalog :
07-531
quantity :
200 µg
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot, immunocytochemistry, immunoprecipitation, proximity ligation assay
citations: 6
| Published Application/Species/Sample/Dilution | Reference |
|---|---|
| Tiwari S, Mizuno K, Ghosh A, Aziz W, Troakes C, Daoud J, et al. Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain. 2016;139:2751-2765 pubmed
|
| |
| |
| |
product information
Catalog Number :
07-531
Subcategory :
Apoptosis & Cancer
Product Name :
Anti-PIR121-1/Sra-1 Antibody
Product Type :
Antibodies
Clonality :
Polyclonal Antibody
Gene ID :
Q96F07
Host Name :
Rabbit
Antigen :
PIR121-1/Sra-1
Conjugate :
Purified
Isotype :
IgG
Product Description :
Anti-PIR121-1/Sra-1 Antibody
Cross Reactivity :
Human;Mouse
Immunogen :
KLH-conjugated, synthetic peptide corresponding to amino acids 872-886 (SQEFQRDKQPNAQPQ-C) of human PIR121-1/Sra-1, with a C-terminal cysteine added for conjugation purposes.
Specificity :
PIR121-1/Sra-1 (aka CYFIP1)
Package Size :
200 µg
Uses :
Immunoprecipitation;Western Blotting
Storage :
stable 2 years at -20°C from date of shipment
company information
EMD Millipore
290 Concord Road
Billerica, Massachusetts 01821
Billerica, Massachusetts 01821
bioscienceshelp@emdchemical.com
https://www.emdmillipore.com888-854-3417
headquarters: United States
EMD Millipore is the Life Science division of Merck KGaA of Darmstadt, Germany
Hundreds of New Antibodies in the areas of:
View all the new antibodies at www.emdmillipore.com.
Hundreds of New Antibodies in the areas of:
|
|
questions and comments
